Cormican M G, Jones R N
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.
Antimicrob Agents Chemother. 1997 Jan;41(1):204-11. doi: 10.1128/AAC.41.1.204.
Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods. LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC50, 0.03 micrograms/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 micrograms/ml). It has limited activity against gram-negative anaerobes.
化合物LB20304是一种带有新型吡咯烷取代基的氟萘啶酮羧酸。通过美国国家临床实验室标准委员会的参考方法，将该药物与环丙沙星、左氧氟沙星、氧氟沙星和曲伐沙星针对800多种病原体进行了比较，其中大多数病原体来自血流感染。LB20304是针对革兰氏阳性菌最具活性的药物，包括对其他氟喹诺酮类药物和糖肽类药物耐药的菌株。LB20304对肠杆菌科细菌的效力（MIC50为0.03微克/毫升）仅次于环丙沙星（0.015微克/毫升）。它对革兰氏阴性厌氧菌的活性有限。
